Kinins and substance P have been implicated in the pathogenesis of inflammatory arthritis by virtue oftheir abilities to induce vasodilation, edema, and pain. The relative biological potencies of these peptides in vivo would depend at least in part upon their rates of catabolism in the joint. We hypothesized that human synovial lining cells may regulate intraarticular levels of kinins and neuropeptides via degradation by cell surface-associated peptidases. We exposed intact human synovial fibroblasts to kinins and substance P, in the presence or absence of specific peptidase inhibitors, and measured the amount of intact substrate remaining and degradation product(s) generated over time. Aminopeptidase M (AmM; EC 3.4.11.2), neutral endopeptidase-24.11 (NEP-24.11; EC 3.4.24.11), and dipeptidyl(amino)peptidase IV (DAP IV; EC 3.4.14.5) were identified on the cell surface of synovial cells. Bradykinin degradation was due entirely to (1.39±0.29 nmol/min per well). Lysylbradykinin was also degraded by NEP-24.11 (0.80±0.19 nmol/min per well); however, in the presence of phosphoramidon, AmM-mediated conversion to bradykinin (3.74±0.46 nmol/min per well) could be demonstrated. The combined actions of NEP-24.11 (0.93±0.15 nmol/min per well) and DAP IV (0.84±0.18 nmol/ min per well) were responsible for the degradation of substance P. AmM (2.44±0.33 nmol /min per well) and NEP-24.11 (1.30±0.45 nmol / min per well) were responsible for the degradation of the opioid peptide, ILeu5lenkephalin. The identity of each of the three peptidases was confirmed via synthetic substrate hydrolysis, inhibition profile, and immunological identification. The profiles of peptidase enzymes identified in cells derived from rheumatoid and osteoarthritic joints were identical. These data demonstrate the human synovial fibroblast to be a rich source of three specific peptidases and suggest that it may play a prominent role in regulating peptide levels in the joint. (J. Clin. Invest. 1992. 90:981-991.)
Introduction
Rheumatoid arthritis is a chronic inflammatory disease that is characterized by the erosion and degradation of cartilage and bone, resulting in joint instability and chronic pain. Several small peptides, most notably kinins and substance P, have attracted recent interest as possible contributors to the pathogenesis and/or propagation of RA by virtue oftheir potent abilities to induce vasodilation, edema, and pain (1, 2) .
Bradykinin and lysylbradykinin are small peptides liberated from alpha2-globulins, called kininogens, by the action of proteolytic enzymes, referred to as kallikreins. The presence of kinins in rheumatoid synovial fluid has been confirmed by several investigators (3) (4) (5) and these levels appear to exceed those found in synovial fluids of noninflammatory arthropathies such as osteoarthritis (OA)' and trauma (5) . The concept that these peptides contribute to the destructive process in the rheumatoid joint is supported by the observations that kinins induce an acute inflammatory response when injected into canine knees (5) and induce bone resorption in, and prostanoid release from, articular tissues in vitro (6, 7) .
Substance P, an 1 l-amino acid peptide neurotransmitter, is released from the peripheral terminals of nociceptive afferent neurons upon antidromic stimulation. Its presence has been confirmed in human rheumatoid synovial fluid (8) and immunohistochemical studies have demonstrated the presence of substance P-containing nerves in synovia from human subjects with RA (9, 10) and in synovia from normal and arthritic animals (11, 12) . Furthermore, intraarticular infusion of substance P exacerbated joint injury in adjuvant-induced arthritis in rats, as evidenced by an increase in bony erosions and joint space narrowing and a decrease in bone density (13) . Finally, substance P is capable ofstimulating the release ofother inflammatory mediators, including prostanoids, IL-1, and histamine, from a variety of cells (14) (15) (16) (17) and can itself function as an immune-modulating agent (2, 18) .
Despite the convincing evidence demonstrating the presence and proinflammatory functions ofkinins and substance P in the joint, little is known regarding the mechanisms by which the actions of these peptides are regulated in this organ. In general, enzymatic catabolism represents a major mechanism by which biological activity of small peptides is regulated (19) . Since the amount of peptidase activity in a target tissue will influence its capacity to respond to a peptide (20) , and since the development of potent peptide antagonists that are based upon modifications ofthe parent molecule must take into consideration stability from enzymatic degradation (20, 21), iden-tification and characterization of peptidase activities in the joint seem warranted.
Previous reports of peptidase activities in articular tissues are scarce, are based predominantly on immunoreactivity rather than on specific functional activity, and/or fail to identify the cellular source of the observed activity (22) (23) (24) (25) . We have observed previously that bradykinin is rapidly degraded upon exposure to human synovial fibroblasts (7) . We hypothesize, therefore, that this human synovial lining cell may serve as an important regulator ofpeptide levels in thejoint via degradation by cell surface-associated peptidases. The synovial lining is in a strategic position to perform this function since it lines the joint cavity, thus giving it access to synovial fluid peptides. Furthermore, the punctuation ofsynovium by small blood vessels would provide a route ofdelivery ofkinins to the tissue and joint space (26) , and substance P-containing nerves are found in close association with the synovial lining layer (9-1 1). In RA this lining layer is greatly hypertrophied (26) and its potential peptide-degrading capabilities, relative to a noninflamed joint, may thereby be greatly magnified.
In these studies, we have examined the ability ofthe human synovial fibroblast to metabolize kinins and substance P. Through the use of specific enzyme inhibitors and the analysis of specific metabolites generated, we sought to identify the synovial cell peptidase(s) responsible for, and the relative contribution of each to, the metabolism ofkinins and substance P. In addition, we have compared the peptidase profile identified in synovial cells derived from patients with the inflammatory arthropathy RA to that of cells derived from patients with the relatively noninflammatory arthropathy OA.
Methods
Reagents. The following materials were purchased: bradykinin, lysylbradykinin, o-phenanthroline, EDTA, amastatin, bestatin, puromycin, phosphoramidon, alanyl-, leucyl-, arginyl-, a-glutamyl-and glycylprolyl-naphthylamides, (piperazine-N,N'bis[2-ethanesulfonic acid]) (PIPES), and Tris buffers (Sigma Chemical Co., St. Louis, MO); substance P and diprotin A (Peninsula Laboratories, Belmont, CA); DME, FCS, penicillin/streptomycin, trypsin, PBS, and amphotericin B (Gibco Laboratories, Grand Island, NY); six-well polystyrene culture dishes (VWR Scientific, Bridgeport, NJ); captopril (SquibbNovo, Inc., Princeton, NJ); MERGETPA (DL-2-mercaptomethyl-3-guanidinoethylthiopropanoic acid), ZINCOV ([2-(N-hydroxy-carboxamido)-4-methylpentanoyl-L-alanyl-glycine amide]); dansyl-DAla-Gly-pNO2-Phe-Gly (Calbiochem-Behring, San Diego, CA); mAbs recognizing CD10/neutral endopeptidase-24. 11 (NEP-24.1 11) (J5; IgG2,.), CD13/aminopeptidase M (AmM) (MY7; IgG1) and CD26/ dipeptidyl(amino)peptidase IV (DAP IV) (Ta 1; IgG1) (Coulter Electronics Inc., Hialeah, FL). The following were kind gifts: recombinant IL-la (Immunex, Seattle, WA); bradykinin [ [1] [2] [3] [4] [5] [6] [7] and Phe-Arg (Drs. Regoli and Drapeau, Sherbrooke University, Sherbrooke, Quebec). Purified AmM (AmM) and AmM antisera were prepared by one of us (Dr. Mizutani) as previously described (27) .
Patient population. Human synovial tissue was obtained from the knees and hips of patients who were undergoing surgical synovectomy or total joint replacement. The patient population consisted of 6 patients with RA and 12 patients with OA. Diagnoses were confirmed either by examination of the patient by one of the investigators (Dr. Bathon) or by chart review and contact with the primary rheumatologist. All patients with RA had either definite or classical disease as defined by criteria of the American College of Rheumatology (28) . Similarly, patients with OA fulfilled published criteria for this disease (29) . Of the six RA patients, five were maintained on low-dose prednisone (<10 mg daily), four on a nonsteroidal antiinflammatory drug, and one each on methotrexate, hydroxychloroquine, and sulfasalazine. Ofthe 12 patients with OA, 6 were taking a nonsteroidal antiinflammatory drug before surgery.
Synovial cell culture. Synovial cell cultures were established from the adherent cells of collagenase-dispersed synovial fragments or by outgrowth from synovial explants, as previously described (7, 30) .
Synovium was dissected free from surrounding tissues, minced into 2-3-mm2 fragments, and enzymatically dissociated with 3 mg/ml of type 2 collagenase (Worthington Biochemical Corp., Freehold, NJ) in DME for 30-60 min. The resulting cell suspension was centrifuged, washed twice with PBS, and the pellet resuspended in DME supplemented with 20% FCS (DME/20% FCS), penicillin (100 U/ml), streptomycin ( 100 ,ug/ml), and amphotericin B (2.5 ,g/ml). Nonad fluorometrically by hydrolysis of the synthetic substrates, a-glutamylnaphthylamide (AmA), alanyl-, leucyl-and arginyl-naphthylamide (AmM), glycyl-prolyl-naphthylamide (DAP IV), and dansyl-D-AlaGly-pNO2-Phe-Gly (NEP), as previously described (35) (36) (37) (38) . Reaction specificity was established by inhibition with appropriate inhibitors, including amastatin (AmM), diprotin A (DAP IV) (39), phosphoramidon, and ZINCOV (NEP-24. 11) (40).
Immunoelectrophoresis. Immunoelectrophoresis (electroimmunoassay) of solubilized (2% Triton X-100) synovial cell homogenate and purified AmM against antisera to human AmM was carried out in 1.0-mm thick 1% (wt/vol) agarose gel containing 1% (vol/vol) Triton X-100 as previously described ( 35, 41 ). Samples were vertically electrophoresed ( 1.5 V/cm for 15 h) directly into antisera-containing gel. After repeated dehydration/hydration ofthe gel to remove soluble protein, the AmM immunoprecipitin line was stained using alanyl-4-methoxy-2-naphthylamide. Peak area measurements were determined using Sigma Scan (Jandel Scientific, Corte Madera, CA).
Flow cytometry analysis. Cells were grown to confluence in 100-mm culture dishes and lifted by vigorous pipeting in PBS containing 1-6 mM EGTA for 5 min. 3 (Fig. 1 A) and Phe-Arg (not shown). No des(Arg9)bradykinin production was observed, even in the presence ofCoCl2, which enhances CPN activity, and inhibition of CPN (MERGEPTA; 10 MiM) had no effect on degradation of bradykinin (not shown). Similarly, inhibition of angiotensin-converting enzyme (ACE) with captopril ( 10 iMM) was without effect. Hydrolysis was nearly completely inhibited, however, by the NEP-24.1 1 inhibitor, phosphoramidon ( Fig. 1 B) denced by the production of des-Tyr'-enkephalin (Fig. 3 B) . In (n = 7) ( (Fig. 4) . These data are consisand OA (NEP-24. 11, 1.16±0.26, n = 2; AmM tent with the known ability of DAP IV to hydrolyze substance mol/min per well, n = 4) derived cell lines (P P (34) and demonstrate that degradation of substance P by ident's t test).
synovial cells is due to the combined actions ofNEP-24. 1 1 and fin metabolism. The opioid peptides, enkephalins, DAP IV (Table I ). This pattern of substance P degradation, as tial substrates for NEP-24. 1 1 (also known as "enwell as the relative enzyme rates, were similar in RA-(NEP-)and AmM (35, 43) . In view ofthe potent appar- 24 munoassay) of pure human AmM and detergent-solubilized synovial cell homogenate produced rocket-shaped precipitates with peak areas proportionate to the amount of sample used (Fig. 5) . When peak areas of immunoreactive AmM ([ iAmM] ) were plotted against the units ofalanyl-naphthylamidase activity inoculated onto the gels, the relationships of [iAmM] to alanyl-naphthylamidase activity were similar for both purified AmM and synovial cell homogenates. NEP-24. 11 and DAP IV activities were also confirmed in synovial cell homogenates (Table II) . NEP-24. 11 activity (14.3±1.4 nmol/min ml; dansyl-D-Ala-Gly-pNO2-Phe-Gly hydrolysis) was specifically inhibited by phosphoramidon (IC50 = 1.5 ,M) and ZINCOV (IC50 = 7 ,uM). Similarly, DAP IV activity ( 1 28± 1 1 nmol / min -ml; glycyl-prolyl-naphthylam- Alanyl-Naphthylamidase (pmol/min) ide hydrolysis) was specifically inhibited by diprotin A (IC50 = 9MM).
Flow cytometric identification ofpeptidases
The membrane antigens, CD10/CALLA, CD13, and CD26, previously described on select populations of hematopoietic cells, have only recently been identified as NEP-24. 11, AmM, and DAP IV, respectively (44) . This recognition enabled us to use mAbs and flow cytometric analysis to further confirm the expression of these enzymes on synovial cells. As shown in Fig.  6 , all three antigens, CD10, CD1 3, and CD26, were consistently expressed in both RA-and OA-derived cells. Furthermore, both the percentage ofpositive cells and the fluorescence intensities for each antigen were similar in RA-and OA-derived cell lines (Table III) . In addition, in one RA cell line studied, expression of all three antigens, CD10, CD1 3, and CD26, persisted during repeated passaging (Table IV) .
Discussion
These studies provide the first direct evidence ofthe presence of three membrane-associated peptidases on human synovial cells. Although plasma-derived CPN activity has been demonstrated in synovial fluid (4, 45) phage-like cells. In contrast, the rheumatoid synovial lining is greatly hypertrophied and a marked increase in the number of both cell populations is observed (26) . That the fibroblastic population of cells plays an important role in the maintenance of normal joint function is suggested by its elaboration ofjoint lubricants such as hyaluronic acid (26) . In addition, the fibroblast appears to play a key role in the destruction of the rheumatoid joint, as evidenced by its potent capacity in vitro to secrete prostaglandins and matrix-degrading proteases, including collagenase, stromelysin, and gelatinases, in response to soluble products of mononuclear cells such as IL-1 (31, 47, 48) . We hypothesized that the fibroblastic synovial cell may also be a potent source of peptide-degrading activity in the joint, and this concept was supported by previous observations in which bradykinin was rapidly degraded by these cells in vitro (7) . Through the use ofspecific peptidase inhibitors, the identification of specific peptide metabolites, and the use of selective synthetic substrates and/or antisera, we have demonstrated the presence of three specific peptidases (NEP-24. 1 1, AmM, and DAP IV) colocalizing on human synovial fibroblasts. Furthermore, the use ofintact rather than broken cells for these studies permitted the localization of these peptidases to the cell surface, suggesting that neither internalization of peptide nor secretion ofenzyme is necessary for peptide metabolism by synovial cells. Finally, we have shown a selective pattern of metabolism for each of the peptides examined and have found that RA-and OA-derived fibroblasts are indistinguishable with regard to relative expression and rates of their peptidase activities. The metabolism ofbradykinin in plasma and vasculature is mediated primarily by ACE, CPN, and CPN-like enzymes (20). In contrast, no ACE, CPN, or CPN-like activities were found in synovial cells. This observation was confirmed by the inability ofMERGEPTA and captopril to decrease, or CoCl2 to enhance, the rate ofbradykinin degradation by synovial cells. It indicates further that adequate removal of serum-containing culture medium was achieved in these studies and that none of the peptidase activities identified in synovial cells could, therefore, be attributed to contamination from calf serum. In fact, the cell surface peptidase NEP-24. 11 was responsible for metabolism of bradykinin via hydrolysis of the Pro7-Phe8 bond to produce the inactive metabolites, BK [1-71 and Phe-Arg (which were subject to further hydrolysis with continued incubation). That degradation ofbradykinin was completely due to NEP-24. 1 1 was confirmed by the ability ofphosphoramidon to completely inhibit metabolism. The recent identification ofthe CD10/CALLA (common acute lymphoblastic leukemia-associated antigen) as NEP-24. 11 (49) enabled us, through the use of immunofluorescence flow cytometry, to further confirm the presence of this peptidase on the synovial cell surface.
No contribution to the degradation of bradykinin from the two other identified peptidases on synovial cells, AmM and DAP IV, would be expected (20). AmM hydrolyzes neutral and basic amino acids, except those involving X-Pro bonds, from the NH2 terminus oflow molecular weight peptides and is thus incapable of hydrolyzing the Arg'-Pro2 NH2 terminus of bradykinin (32, 35) . DAP IV hydrolyzes NH2 terminal X-Pro dipeptides, except those involving Pro in the third position, and likewise is incapable of hydrolyzing the Arg'-Pro2-Pro3 NH2 terminus of bradykinin (50) (51) (52) .
Lysylbradykinin was also metabolized by the synovial cell to biologically inactive metabolites, primarily through the action of NEP-24. 11. However, when this enzyme was inhibited with phosphoramidon, conversion oflysylbradykinin to bradykinin was observed and was due to the action of AmM. Identification of the enzyme as AmM was suggested in intact cells by the ability of amastatin to completely inhibit the conversion of lysylbradykinin to bradykinin. Further confirmation was provided in studies of cell lysates in which the enzyme hydrolyzed alanyl-naphthylamide more rapidly than leucyl-and arginylnaphthylamides, was 50-fold more sensitive to inhibition by amastatin than bestatin, was relatively resistant to puromycin, and was unaffected by captopril, MERGEPTA, phosphoramidon, and diprotin A. In addition, the ratio of alanyl-naphthylamidase activity to amount ofimmunoreactive AmM found in synovial cell lysates was comparable to that for purified AmM. Collectively, these characteristics differentiate AmM from ACE, CPN, NEP-24. 11, DAP IV, and from other neutral/basic amino acid selective aminopeptidases, including leucine aminopeptidase (EC 3.4.11.1) and aminopeptidase B (EC 3.4.11.6) (35, 37) . Final confirmation of the presence of this exopeptidase on synovial cells was provided by immunofluorescent staining with an mAb to the leukocyte antigen CD 13 that has recently been identified as AmM/AmN (53) .
The impressive ability of relatively small numbers of synovial fibroblasts in vitro to degrade nanomole amounts ofkinins within minutes, coupled with their high level of CD IO antigen expression, are indicative of a large amount of NEP-24. 11 on the membranes of these cells. This observation has several potential clinical implications. The presence and amount ofNEP-24.1 1 may explain in part the relative insensitivity ofuntreated human synovial fibroblasts to bradykinin (7) despite B2 kinin receptors that number -36,000 sites per cell (54) . In addition, the recent demonstration ofmeasurable NEP-24. 1 1 activity in synovial fluids (55) suggests that the synovial fibroblast, in addition to expressing NEP-24. 11 on its cell surface, may also have the capacity to secrete this enzyme into the joint cavity. The similar intensity of NEP-24. 11 expression on cells from OA and RA joints suggests that the potent ability ofsynovial fibroblasts to degrade kinins is not disease specific but rather may constitute a normal physiological function for these synovial lining cells. The synovial lining is in a strategic position to perform this function since it not only is in direct contiguity to the joint cavity, where bradykinin may be generated spontaneously (56), but in addition would be expected to encounter kinins diffusing in from synovial vasculature. Since our data show that, cell per cell in vitro, RA-and OA-derived fibroblasts exhibit equivalent expression of NEP-24. 11, it is likely in vivo that the intensely cellular RA synovium would exhibit increased expression of NEP-24. 11 activity compared with the relatively hypocellular normal and OA synovia. In support of this concept, Sreedharan et al. (24) have demonstrated increased NEP-24. 11 activity in sonicates of RA synovium compared with those ofOA or traumatic origin, although the cell source was not identified. Furthermore, precedent for enhanced peptidase activity (NEP-24. 11 ) in conjunction with cell growth exists in transformed human tracheal epithelial cells (57) .
The ability of synovial cells to convert lysylbradykinin to bradykinin through the action of AmM, although also quite substantial, is ofuncertain physiological significance. Although kallikrein-like activity in human synovial fluid and tissues has been demonstrated, controversy persists as to whether the predominant activity is of plasma (which would generate bradykinin) or oftissue (which would generate lysylbradykinin) origin (58, 59) . Furthermore, changes in the relative ratio oflysylbradykinin to bradykinin over time would be unlikely to influence tissue responses since the two peptides exhibit equivalent affinities for the B2 kinin receptor and, consequently, equivalent potencies in inducing physiological effects in most systems studied (20). Thus, although AmM catalyzes the conversion of lysylbradykinin to bradykinin, NEP-24. 11 is the enzyme responsible for the biological inactivation of both kinins.
AmM clearly participates in the metabolism of a variety of other small peptides, however, including the low molecular weight opioid peptides known as "enkephalins" ( 19, 60, 61) . Although the role of opioids in endogenous pain control of arthritic animals has been examined primarily in brain and spinal cord tissues, recent data suggest that peripheral opioid receptors exist (62, 63) and mediate local analgesic responses (64) in articular and periarticular structures, and immunohistochemical studies have documented the presence ofenkephalins in synovial tissues (9, 63) . Furthermore, opioids may alter inflammatory processes by inhibiting the release of vasodilatory neurotransmitters from sensory nerve terminals (65) and by modulating immune cell responses such as chemotaxis, proliferation, and cytotoxicity (66) (67) (68) .
We evaluated, therefore, the ability of the synovial fibro- (71) .
As with bradykinin, the potent capacity for synovial fibroblasts to degrade neuropeptides was not disease specific, as indicated by the similar rates of enzyme activities and corresponding antigen expression in RA-and OA-derived cells.
These data suggest that regulation of intraarticular neuropeptide levels may also be a normal physiological function of the synovial lining and this function might also be expected to be enhanced in vivo in hypercellular, inflamed synovia. Indeed, several investigators have shown by immunohistochemical techniques a relative decrease in substance P and/or enkephalin immunoreactivity in the synovia of patients with RA (9, 10) and rats with adjuvant arthritis ( 11) compared with normal and OA patients or normal rats. Although this decrease may be due in part to an unexplained decrease in number of nerve fibers themselves ( 10, 11 ) , it is tempting to speculate that more vigorous metabolism of these peptides within the inflamed, hypercellular synovia may also have contributed to the decreased immunoreactivity.
Hypertrophy of the synovial lining has long been regarded as an unfavorable occurrence in the development of RA because of the presumed concomittant increase in the release of proinflammatory mediators such as proteolytic enzymes and prostanoids (72) . Our data, however, in illustrating the ability of synovial fibroblasts to metabolize the proinflammatory peptides, kinins, and substance P, suggest a unique antiinflammatory function for the synovial lining that is likely to be enhanced with progressive hypertrophy of this lining. Paradoxically, enhanced degradation of opioids by synovial cell peptidases could promote intraarticular algesia but, as yet, data supporting a role for opioids in the modulation of pain and inflammation in the joint remain circumstantial.
The total amount of peptidase activity in synovia of inflamed versus noninflamed joints in vivo is unlikely to depend entirely on the relative numbers of fibroblastic cells, however. Macrophages, the other prominent cell type in synovial lining, may themselves express peptidase activity in a profile similar to or different from that of fibroblastic cells. Although we did not examine peptidase activity in purified populations of synovial macrophages, to our knowledge, only AmM, not NEP-24. 1 1 or DAP IV, activity has been demonstrated on macrophages from other organs (44) . Alternatively, soluble products of macrophages might influence the in vivo expression of peptidases on fibroblastic cells. We failed to observe a change in the immunofluorescent expression of NEP-24. 11, AmM, or DAP IV on fibroblastic cells with progressive passaging and time in culture. Since the macrophage subpopulation of primary synovial cell cultures routinely disappears by the first or second passage (31 ) , this observation suggests in fact that fibroblastic peptidase expression is not dependent upon the physical presence of macrophages or their soluble products. The failure of IL-1 treatment of synovial fibroblasts to alter the rates of NEP-24.1 1-, AmM-and DAP IV-mediated kinin and neuropeptide degradation (unpublished observations) further supports this concept, although other macrophage-associated cytokines have not been examined.
The persistence over time in culture of, and lack of effect of IL-1 on, peptidase expression on synovial cells is in direct contrast to the expression of proteases, such as collagenase and stromelysin, by synovial cells, in that secreted levels are high in primary culture, become unmeasurable by the first or second passage, but can be subsequently reinduced by IL-1 (31, 47, 48) . That peptidase and protease expression are regulated differently is further illustrated by the ability of phorbol esters, in rabbit synovial cells, to downregulate NEP-24. 11 mRNA expression while upregulating that ofcollagenase and stromelysin (46) . This differential regulation could have important implications in therapeutic attempts to target inhibition of one, but not the other, class of enzymes. Identification of physiologically relevant factors or pharmacological agents that regulate peptidase activity within the joint may provide important insights into the pathogenesis and treatment of inflammatory arthritis. Glucocorticoids, for example, upregulate mRNA expression and functional activity of NEP-24. 11 in transformed human tracheal epithelial cells (57) and this action may constitute an additional mechanism, in the joint, by which steroids exert antiinflammatory effects. Finally, an even broader role for these peptidases beyond the degradation of small peptides has been suggested by the ability of NEP-24. 1 1, or an NEP-24.1 1-like enzyme, to inactivate IL-1 (73) and to activate procollagenase (74), as well as by the ability ofDAP IV to promote cell attachment (75, 76) .
